HRP20201469T1 - Derivati tetrahidroizokinolina - Google Patents
Derivati tetrahidroizokinolina Download PDFInfo
- Publication number
- HRP20201469T1 HRP20201469T1 HRP20201469TT HRP20201469T HRP20201469T1 HR P20201469 T1 HRP20201469 T1 HR P20201469T1 HR P20201469T T HRP20201469T T HR P20201469TT HR P20201469 T HRP20201469 T HR P20201469T HR P20201469 T1 HRP20201469 T1 HR P20201469T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- dihydroisoquinolin
- dichlorophenyl
- ethanone
- chloro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188174 | 2014-10-08 | ||
| EP15775688.3A EP3204359B1 (en) | 2014-10-08 | 2015-10-06 | Tetrahydroisoquinoline derivatives |
| PCT/EP2015/073053 WO2016055479A1 (en) | 2014-10-08 | 2015-10-06 | Tetrahydroisoquinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201469T1 true HRP20201469T1 (hr) | 2020-12-11 |
Family
ID=51790569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201469TT HRP20201469T1 (hr) | 2014-10-08 | 2015-10-06 | Derivati tetrahidroizokinolina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10105359B2 (enExample) |
| EP (1) | EP3204359B1 (enExample) |
| JP (1) | JP6622299B2 (enExample) |
| CN (1) | CN107001278B (enExample) |
| BR (1) | BR112017007123B1 (enExample) |
| CA (1) | CA2963951C (enExample) |
| CY (1) | CY1123417T1 (enExample) |
| DK (1) | DK3204359T3 (enExample) |
| EA (1) | EA035544B1 (enExample) |
| ES (1) | ES2821821T3 (enExample) |
| HR (1) | HRP20201469T1 (enExample) |
| HU (1) | HUE050664T2 (enExample) |
| LT (1) | LT3204359T (enExample) |
| PL (1) | PL3204359T3 (enExample) |
| PT (1) | PT3204359T (enExample) |
| RS (1) | RS60933B1 (enExample) |
| SI (1) | SI3204359T1 (enExample) |
| WO (1) | WO2016055479A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018010192A (es) * | 2016-02-25 | 2019-01-31 | Asceneuron S A | Inhibidores de glucosidasa. |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| CN107698433A (zh) * | 2017-09-12 | 2018-02-16 | 潍坊滨海石油化工有限公司 | 苯乙酸的制备方法 |
| CN111432847A (zh) | 2017-12-01 | 2020-07-17 | Ucb生物制药有限责任公司 | 显像剂 |
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| MY210361A (en) | 2019-07-01 | 2025-09-13 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| PH12021552819A1 (en) * | 2019-07-01 | 2022-09-28 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| WO2021216973A1 (en) * | 2020-04-24 | 2021-10-28 | The Regents Of The University Of California | Nurr1 receptor modulators and uses thereof |
| CN111943930B (zh) * | 2020-08-25 | 2022-11-01 | 南京三元阳普医药科技有限公司 | Lasmiditan的合成工艺 |
| MD4200280T2 (ro) * | 2020-10-07 | 2024-08-31 | Lilly Co Eli | Derivați de fenil-3,4-dihidroizochinolin-2(1H)-il-etan-1-onă în calitate de modulatori alosterici pozitivi ai receptorului de dopamină D1 |
| CN116507332A (zh) | 2020-12-03 | 2023-07-28 | Ucb生物制药有限责任公司 | 八氢异喹啉基衍生物 |
| FI4263517T3 (fi) | 2020-12-18 | 2024-12-09 | UCB Biopharma SRL | Substituoitu tetrahydroisokinoliinijohdannainen d1-positiivisena allosteerisenä modulaattorina |
| JP7777589B2 (ja) | 2020-12-18 | 2025-11-28 | ユーシービー バイオファルマ エスアールエル | ジヒドロイソキノリニル誘導体 |
| ES3004257T3 (en) * | 2020-12-18 | 2025-03-12 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| KR20230121867A (ko) * | 2020-12-18 | 2023-08-21 | 유씨비 바이오파마 에스알엘 | 무정형 고체 분산체 |
| MX2023010540A (es) | 2021-03-08 | 2023-11-24 | Lilly Co Eli | Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia. |
| AU2022234226B2 (en) | 2021-03-09 | 2025-08-14 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
| CN114671810B (zh) * | 2022-03-21 | 2024-03-22 | 济南鸿湾生物技术有限公司 | 一种咪唑苯脲的制备方法 |
| CN115611768B (zh) * | 2022-11-14 | 2024-03-05 | 郑州大学 | 一种3,4-二氯苯腈的合成方法 |
| CN118724764B (zh) * | 2024-06-07 | 2025-11-18 | 绍兴文理学院 | 一种芳基伯磺酰胺类化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766131A (en) * | 1980-10-17 | 1988-08-23 | Pennwalt Corporation | 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics |
| MXPA04005988A (es) * | 2001-12-19 | 2004-09-27 | Lundbeck & Co As H | 3,4-dihidro-1h-isoquinolin-2-il-derivados. |
| ES2342083T3 (es) * | 2004-04-29 | 2010-07-01 | Aventis Pharmaceuticals Inc. | 3-piperidinilisocroman-5-oles como agonistas de dopamina. |
| RU2009136330A (ru) * | 2007-03-01 | 2011-04-10 | Янссен Фармацевтика Н.В. (Be) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора |
-
2015
- 2015-10-06 HR HRP20201469TT patent/HRP20201469T1/hr unknown
- 2015-10-06 US US15/517,795 patent/US10105359B2/en active Active
- 2015-10-06 ES ES15775688T patent/ES2821821T3/es active Active
- 2015-10-06 JP JP2017518989A patent/JP6622299B2/ja active Active
- 2015-10-06 HU HUE15775688A patent/HUE050664T2/hu unknown
- 2015-10-06 LT LTEP15775688.3T patent/LT3204359T/lt unknown
- 2015-10-06 DK DK15775688.3T patent/DK3204359T3/da active
- 2015-10-06 CA CA2963951A patent/CA2963951C/en active Active
- 2015-10-06 PL PL15775688.3T patent/PL3204359T3/pl unknown
- 2015-10-06 WO PCT/EP2015/073053 patent/WO2016055479A1/en not_active Ceased
- 2015-10-06 EA EA201790785A patent/EA035544B1/ru not_active IP Right Cessation
- 2015-10-06 RS RS20201139A patent/RS60933B1/sr unknown
- 2015-10-06 SI SI201531348T patent/SI3204359T1/sl unknown
- 2015-10-06 EP EP15775688.3A patent/EP3204359B1/en active Active
- 2015-10-06 BR BR112017007123-1A patent/BR112017007123B1/pt not_active IP Right Cessation
- 2015-10-06 CN CN201580064005.3A patent/CN107001278B/zh not_active Expired - Fee Related
- 2015-10-06 PT PT157756883T patent/PT3204359T/pt unknown
-
2020
- 2020-09-30 CY CY20201100923T patent/CY1123417T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE050664T2 (hu) | 2020-12-28 |
| US10105359B2 (en) | 2018-10-23 |
| BR112017007123B1 (pt) | 2023-01-31 |
| JP2017530185A (ja) | 2017-10-12 |
| EP3204359B1 (en) | 2020-07-01 |
| WO2016055479A1 (en) | 2016-04-14 |
| PT3204359T (pt) | 2020-09-24 |
| ES2821821T3 (es) | 2021-04-27 |
| RS60933B1 (sr) | 2020-11-30 |
| EP3204359A1 (en) | 2017-08-16 |
| US20170304292A1 (en) | 2017-10-26 |
| DK3204359T3 (da) | 2020-09-14 |
| EA201790785A1 (ru) | 2017-10-31 |
| CA2963951A1 (en) | 2016-04-14 |
| CN107001278B (zh) | 2020-11-24 |
| JP6622299B2 (ja) | 2019-12-18 |
| BR112017007123A2 (pt) | 2017-12-19 |
| CY1123417T1 (el) | 2021-12-31 |
| CA2963951C (en) | 2023-02-28 |
| PL3204359T3 (pl) | 2021-03-22 |
| LT3204359T (lt) | 2020-10-12 |
| CN107001278A (zh) | 2017-08-01 |
| SI3204359T1 (sl) | 2020-10-30 |
| EA035544B1 (ru) | 2020-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
| JP2017530185A5 (enExample) | ||
| TWI883352B (zh) | 稠環化合物 | |
| RU2018123779A (ru) | Новые соединения | |
| JP2016517878A5 (enExample) | ||
| JP6342393B2 (ja) | 置換型ピラゾロン化合物及び使用方法 | |
| JP2016523911A5 (enExample) | ||
| HRP20231310T1 (hr) | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene | |
| JP2016500073A5 (enExample) | ||
| IL273924B1 (en) | Muscarinic acetylcholine M4 receptor antagonists | |
| RU2507204C2 (ru) | Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона | |
| RU2016124178A (ru) | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет | |
| HRP20200962T1 (hr) | Novi spojevi | |
| HRP20171670T1 (hr) | Spojevi i sastavi za moduliranje egfr-aktiviteta | |
| RU2018140092A (ru) | Новые пиразолпиримидиновые производные | |
| JP2019508384A (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| HRP20150868T1 (hr) | Derivati kinolina i kinoksalina kao inhibitori kinaze | |
| HRP20130106T1 (hr) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| JP2013539777A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| HRP20211678T1 (hr) | N-supstituirani derivati indola kao modulatori receptora pge2 | |
| HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| JP2017532360A5 (enExample) | ||
| HRP20170119T1 (hr) | Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije | |
| ES2768399T3 (es) | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |